Targretin bexarotene capsules: Phase II; marketed to treat refractory cutaneous T cell lymphoma

LGND reported that in a 50-patient, dose-ranging trial lasting 12 weeks with the option

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE